Completed PHASE3 INTERVENTIONAL NCT00003647

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma

Sponsor: Vical

Conditions Recurrent Melanoma Stage III Melanoma Stage IV Melanoma

Interventions allovectin-7 allovectin-7/dacarbazine dacarbazine

Updated 6 times since 2017 Last updated: Jul 23, 2008 Started: Jul 31, 1998 Completion: Sep 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003647, this PHASE3 trial focuses on Recurrent Melanoma and Stage III Melanoma and remains completed. Sponsored by Vical, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vical

Data source: Vical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bakersfield, United States , Baltimore, United States , Billings, United States , Bismarck, United States , Bloomington, United States , Brooklyn, United States , Chicago, United States , Columbus, United States , Danville, United States , Decatur, United States and 32 more locations